FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Trainer

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Pituitary Gland

Concepts & Ideas

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Ilias Perogamvros; David W Ray; Peter J Trainer
Regulation of cortisol bioavailability--effects on hormone measurement and action.
C E Higham; A Lewis; N M Martin; V Moyes; J Newell-Price; A B Atkinson; S Aylwin; Martin Bidlingmaier; W M Drake; Peter J Trainer
Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
I Perogamvros; L Aarons; A G Miller; Peter J Trainer; David W Ray
Corticosteroid-binding globulin regulates cortisol pharmacokinetics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Trainer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ilias Perogamvros; David W Ray; Peter J Trainer
Regulation of cortisol bioavailability--effects on hormone measurement and action.
Nature reviews. Endocrinology 2012;8(12):717-27.
2012: C E Higham; A Lewis; N M Martin; V Moyes; J Newell-Price; A B Atkinson; S Aylwin; Martin Bidlingmaier; W M Drake; Peter J Trainer
Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
The Journal of clinical endocrinology and metabolism 2012;97(4):1187-93.
2011: I Perogamvros; L Aarons; A G Miller; Peter J Trainer; David W Ray
Corticosteroid-binding globulin regulates cortisol pharmacokinetics.
Clinical endocrinology 2011;74(1):30-6.
2010: Paul Leach; Ahmed H Abou-Zeid; Tara Kearney; Julian Davis; Peter J Trainer; Kanna Gnanalingham
Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve.
Neurosurgery 2010;67(5):1205-12.
2010: I Perogamvros; B G Keevil; David W Ray; Peter J Trainer
Salivary cortisone is a potential biomarker for serum free cortisol.
The Journal of clinical endocrinology and metabolism 2010;95(11):4951-8.
2010: I Perogamvros; C Underhill; D E Henley; K D Hadfield; William G Newman; David W Ray; S L Lightman; G L Hammond; Peter J Trainer
Novel corticosteroid-binding globulin variant that lacks steroid binding activity.
The Journal of clinical endocrinology and metabolism 2010;95(10):E142-50.
2010: Ilias Perogamvros; Laura J Owen; Brian G Keevil; Georg Brabant; Peter J Trainer
Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing.
Clinical endocrinology 2010;72(1):17-21.
2009: Peter J Trainer
ACROSTUDY: the first 5 years.
European journal of endocrinology / European Federation of Endocrine Societies 2009;161 Suppl 1():S19-24.
2009: Peter J Trainer; Shereen Ezzat; Gwyn A D'Souza; Gary Layton; Christian J Strasburger
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
Clinical endocrinology 2009;71(4):549-57.
2009: C E Higham; S Rowles; D Russell-Jones; A M Umpleby; Peter J Trainer
Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
The Journal of clinical endocrinology and metabolism 2009;94(7):2459-63.
2009: C E Higham; T T Chung; J Lawrance; William M Drake; Peter J Trainer
Long-term experience of pegvisomant therapy as a treatment for acromegaly.
Clinical endocrinology 2009;71(1):86-91.
2009: Angela N Paisley; Susannah V Rowles; D Brandon; Peter J Trainer
A subnormal peak cortisol response to stimulation testing does not predict a subnormal cortisol production rate.
The Journal of clinical endocrinology and metabolism 2009;94(5):1757-60.
2009: Angela N Paisley; Ashley S Izzard; Islay Gemmell; Kennedy Cruickshank; Peter J Trainer; Anthony M Heagerty
Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly.
The Journal of clinical endocrinology and metabolism 2009;94(4):1111-7.
2009: Ana Pokrajac; Jan Frystyk; Allan Flyvbjerg; Peter J Trainer
Pituitary-independent effect of octreotide on IGF1 generation.
European journal of endocrinology / European Federation of Endocrine Societies 2009;160(4):543-8.
2009: C A Berg; A Pokrajac; Martin Bidlingmaier; C J Strasburger; Stephen M Shalet; Peter J Trainer
Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
Clinical endocrinology 2009;70(3):439-45.
2008: Camilo Jimenez; Pia Burman; Roger Abs; David R Clemmons; William M Drake; Kent R Hutson; Michael Messig; Michael O Thorner; Peter J Trainer; Robert Gagel
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.
European journal of endocrinology / European Federation of Endocrine Societies 2008;159(5):517-23.
2007: Angela N Paisley; Susannah V Rowles; Margaret E Roberts; Susan M Webb; X Badia; L Prieto; Stephen M Shalet; Peter J Trainer
Treatment of acromegaly improves quality of life, measured by AcroQol.
Clinical endocrinology 2007;67(3):358-62.
2007: Angela N Paisley; Margaret E Roberts; Peter J Trainer
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
Clinical endocrinology 2007;66(5):723-6.
2007: Angela N Paisley; K Hayden; A Ellis; J Anderson; Gilbert E Wieringa; Peter J Trainer
Pegvisomant interference in GH assays results in underestimation of GH levels.
European journal of endocrinology / European Federation of Endocrine Societies 2007;156(3):315-9.
2007: Claire E Higham; Andreas Jostel; Peter J Trainer
IGF-I measurements in the monitoring of GH therapy.
Pituitary 2007;10(2):159-63.
2007: Craig Parkinson; Pia Burman; Michael Messig; Peter J Trainer
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
The Journal of clinical endocrinology and metabolism 2007;92(1):190-5.
2006: Angela N Paisley; Chris J O'Callaghan; Krzysztof Lewandowski; Craig Parkinson; Margaret E Roberts; William M Drake; John P Monson; Peter J Trainer; Harpal S Randeva
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
The Journal of clinical endocrinology and metabolism 2006;91(11):4635-40.
2006: Peter J Trainer; Julian Barth; Cathie Sturgeon; Gilbert Wieringaon
Consensus statement on the standardisation of GH assays.
European journal of endocrinology / European Federation of Endocrine Societies 2006;155(1):1-2.
2006: Angela N Paisley; Peter J Trainer
Recent developments in the therapy of acromegaly.
Expert opinion on investigational drugs 2006;15(3):251-6.
2005: Ariel L Barkan; Pia Burman; David R Clemmons; William M Drake; Robert Gagel; Philip E Harris; Peter J Trainer; Aart Jan Van der Lely; Mary Lee Vance
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
The Journal of clinical endocrinology and metabolism 2005;90(10):5684-91.
2005: Susannah V Rowles; L Prieto; X Badia; Stephen M Shalet; Susan M Webb; Peter J Trainer
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.
The Journal of clinical endocrinology and metabolism 2005;90(6):3337-41.
2005: William M Drake; R A Loureiro; Craig Parkinson; John P Monson; G Michael Besser; Peter J Trainer
Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
European journal of endocrinology / European Federation of Endocrine Societies 2005;152(1):47-51.
2004: Angela N Paisley; Peter J Trainer; William M Drake
The place of pegvisomant in the acromegaly treatment algorithm.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2004;14 Suppl A():S101-6.
2004: Angela N Paisley; Peter J Trainer; William M Drake
Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Expert opinion on biological therapy 2004;4(3):421-5.
2004: Craig Parkinson; Allan Flyvbjerg; Peter J Trainer
High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2004;14(1):59-65.
2004: Angela N Paisley; Peter J Trainer
The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly.
Hormone research 2004;62 Suppl 1():83-8.
2004: Ana Pokrajac-Simeunovic; Peter J Trainer
Pitfalls in the diagnosis of acromegaly.
Hormone research 2004;62 Suppl 3():74-8.
2003: Annice Mukherjee; John P Monson; Peter J Jönsson; Peter J Trainer; Stephen M Shalet
Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders.
The Journal of clinical endocrinology and metabolism 2003;88(12):5865-70.
2003: Craig Parkinson; M Kassem; L Heickendorff; Allan Flyvbjerg; Peter J Trainer
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
The Journal of clinical endocrinology and metabolism 2003;88(12):5650-5.
2003: Angela N Paisley; Peter J Trainer
Medical treatment in acromegaly.
Current opinion in pharmacology 2003;3(6):672-7.
2003: William M Drake; Susannah V Rowles; Margaret E Roberts; F K Fode; G Michael Besser; John P Monson; Peter J Trainer
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
European journal of endocrinology / European Federation of Endocrine Societies 2003;149(6):521-7.
2003: David R Clemmons; Kazuo Chihara; Pamela U Freda; Ken K Y Ho; Anne Klibanski; Shlomo Melmed; Stephen M Shalet; Christian J Strasburger; Peter J Trainer; Michael O Thorner
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
The Journal of clinical endocrinology and metabolism 2003;88(10):4759-67.
2003: C Parkinson; J A Scarlett; Peter J Trainer
Pegvisomant in the treatment of acromegaly.
Advanced drug delivery reviews 2003;55(10):1303-14.
2003: Craig Parkinson; A J Whatmore; A P Yates; William M Drake; G Brabant; P E Clayton; Peter J Trainer
The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Clinical endocrinology 2003;59(2):168-74.
2003: William M Drake; Peter J Trainer
Clinical use of pegvisomant for the treatment of acromegaly.
Treatments in endocrinology 2003;2(6):369-74.
2002: Peter J Trainer
Corticosteroids and pregnancy.
Seminars in reproductive medicine 2002;20(4):375-80.
2002: John J Kopchick; C Parkinson; E C Stevens; Peter J Trainer
Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Endocrine reviews 2002;23(5):623-46.
2002: Craig Parkinson; Andrew G Renehan; W D J Ryder; Sarah T O'Dwyer; Stephen M Shalet; Peter J Trainer
Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
Clinical endocrinology 2002;57(1):59-64.
2002: Peter J Trainer
A giant's step forward.
Clinical endocrinology 2002;56(4):423-5.
2002: Craig Parkinson; William M Drake; Margaret E Roberts; K Meeran; G Michael Besser; Peter J Trainer
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
The Journal of clinical endocrinology and metabolism 2002;87(4):1797-804.
2002: Craig Parkinson; William M Drake; Gilbert E Wieringa; A P Yates; G Michael Besser; Peter J Trainer
Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Clinical endocrinology 2002;56(3):303-11.
2001: Aart Jan Van der Lely; R K Hutson; Peter J Trainer; G M Besser; Ariel L Barkan; Laurence Katznelson; Anne Klibanski; VS Herman-Bonert; Shlomo Melmed; Mary Lee Vance; Pamela U Freda; P M Stewart; Keith E Friend; David R Clemmons; G Johannsson; Stavros Stavrou; David M Cook; Lawrence S Phillips; Christian J Strasburger; S Hackett; KA Zib; R J Davis; JA Scarlett; M O Thorner
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
Lancet 2001;358(9295):1754-9.
2001: Craig Parkinson; W D J Ryder; Peter J Trainer
The relationship between serum GH and serum IGF-I in acromegaly is gender-specific.
The Journal of clinical endocrinology and metabolism 2001;86(11):5240-4.
2001: William M Drake; Craig Parkinson; G Michael Besser; Peter J Trainer
Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Trends in endocrinology and metabolism: TEM 2001;12(9):408-13.
2001: William M Drake; Craig Parkinson; Scott A Akker; John P Monson; G Michael Besser; Peter J Trainer
Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
European journal of endocrinology / European Federation of Endocrine Societies 2001;145(4):451-6.
2001: Craig Parkinson; Peter J Trainer
The place of pegvisomant in the management of acromegaly.
Expert opinion on investigational drugs 2001;10(9):1725-35.
2001: Peter J Trainer; William M Drake; LA Perry; NF Taylor; G Michael Besser; John P Monson
Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
The Journal of clinical endocrinology and metabolism 2001;86(7):2989-92.
2001: Gregory A Kaltsas; Andrea M Isidori; D Florakis; Peter J Trainer; Cecilia Camacho-Hubner; Farhad Afshar; Ian Sabin; J P Jenkins; Shern L Chew; John P Monson; G Michael Besser; Ashley B Grossman
Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
The Journal of clinical endocrinology and metabolism 2001;86(4):1645-52.
2000: Craig Parkinson; Peter J Trainer
Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2000;10 Suppl B():S119-23.
2000: Gregory A Kaltsas; John Newell-Price; Peter J Trainer; G M Besser; A B Grossman
Complications of inferior petrosel sinus sampling.
The Journal of clinical endocrinology and metabolism 2000;85(4):1741.
1999: Peter J Trainer; M Palermo; J M Kirk; Giuseppe Fanciulli; L H Perry; Giuseppe Delitala; G Michael Besser
Quantitative growth hormone secretion and final adult height.
Clinical endocrinology 1999;51(5):597-602.
1999: Craig Parkinson; Peter J Trainer
Growth hormone receptor antagonists therapy for acromegaly.
Baillière's best practice & research. Clinical endocrinology & metabolism 1999;13(3):419-30.
1999: Marta Korbonits; Gregory A Kaltsas; LA Perry; Ashley B Grossman; John P Monson; G Michael Besser; Peter J Trainer
Hexarelin as a test of pituitary reserve in patients with pituitary disease.
Clinical endocrinology 1999;51(3):369-75.
1999: Marta Korbonits; J A Little; ML Forsling; G Tringali; A Costa; P Navarra; Peter J Trainer; Ashley B Grossman
The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants.
Journal of neuroendocrinology 1999;11(7):521-8.
1999: Marta Korbonits; Gregory A Kaltsas; LA Perry; Pietro Putignano; Ashley B Grossman; G Michael Besser; Peter J Trainer
The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
The Journal of clinical endocrinology and metabolism 1999;84(7):2489-95.
1999: S A A Sohaib; JA Hanson; John Newell-Price; Peter J Trainer; John P Monson; A B Grossman; G M Besser; Rodney H Reznek
CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome.
AJR. American journal of roentgenology 1999;172(4):997-1002.
1999: JA Hanson; S A A Sohaib; John Newell-Price; N Islam; John P Monson; Peter J Trainer; Ashley Grossman; G M Besser; Rodney H Reznek
Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome.
The Journal of clinical endocrinology and metabolism 1999;84(2):602-5.
1999: Gregory A Kaltsas; M G Giannulis; John Newell-Price; JE Dacie; C Thakkar; Farhad Afshar; John P Monson; Ashley B Grossman; G Michael Besser; Peter J Trainer
A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome.
The Journal of clinical endocrinology and metabolism 1999;84(2):487-92.
1998: William M Drake; D Coyte; Cecilia Camacho-Hübner; N M Jivanji; Gregory A Kaltsas; DF Wood; Peter J Trainer; Ashley B Grossman; G Michael Besser; John P Monson
Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
The Journal of clinical endocrinology and metabolism 1998;83(11):3913-9.
1998: John Newell-Price; Peter J Trainer; M Besser; Ashley Grossman
The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.
Endocrine reviews 1998;19(5):647-72.
1998: Marta Korbonits; RA Jacobs; S J B Aylwin; Jacky M Burrin; Patricia Dahia; John P Monson; J Honegger; R Fahlbush; Peter J Trainer; Shern L Chew; G Michael Besser; Ashley B Grossman
Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
The Journal of clinical endocrinology and metabolism 1998;83(10):3624-30.
1998: Peter J Trainer
Too much of a good thing.
Clinical endocrinology 1998;49(3):285-6.
1998: J Lado-Abeal; J Rodriguez-Arnao; John Newell-Price; LA Perry; Ashley B Grossman; G Michael Besser; Peter J Trainer
Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.
The Journal of clinical endocrinology and metabolism 1998;83(9):3083-8.
1998: Peter J Trainer; Russell J Woods; Marta Korbonits; V Popovic; Paul M Stewart; P J Lowry; Ashley B Grossman
The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human.
The Journal of clinical endocrinology and metabolism 1998;83(5):1611-4.
1997: JJ Mukherjee; N Islam; Gregory A Kaltsas; David G Lowe; M Charlesworth; Farhad Afshar; Peter J Trainer; John P Monson; G Michael Besser; Ashley B Grossman
Clinical, radiological and pathological features of patients with Rathke's cleft cysts: tumors that may recur.
The Journal of clinical endocrinology and metabolism 1997;82(7):2357-62.
1997: Marta Korbonits; Peter J Trainer; J A Little; R Edwards; P G Kopelman; G Michael Besser; F Svec; Ashley B Grossman
Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity.
Clinical endocrinology 1997;46(6):751-7.
1996: Marta Korbonits; Peter J Trainer; M L Nelson; I Howse; P G Kopelman; G M Besser; Ashley B Grossman; F Svec
Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution.
Clinical endocrinology 1996;45(6):699-706.
1996: Marta Korbonits; Peter J Trainer; Giuseppe Fanciulli; O Oliva; Antonello Pala; A Dettori; M Besser; Giuseppe Delitala; Ashley B Grossman
L-arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide.
European journal of endocrinology / European Federation of Endocrine Societies 1996;135(5):543-7.
1996: Marta Korbonits; J A Little; Cecilia Camacho-Hübner; Peter J Trainer; G Michael Besser; Ashley B Grossman
Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.
Growth regulation 1996;6(2):110-20.
1995: John Newell-Price; Peter J Trainer; L Perry; J Wass; Ashley Grossman; M Besser
A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome.
Clinical endocrinology 1995;43(5):545-50.
1995: Marta Korbonits; Peter J Trainer; G Michael Besser
The effect of an opiate antagonist on the hormonal changes induced by hexarelin.
Clinical endocrinology 1995;43(3):365-71.
1995: Marta Korbonits; Peter J Trainer; R Edwards; G Michael Besser; Ashley B Grossman
Benzodiazepines attenuate the pituitary-adrenal responses to corticotrophin-releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome.
Clinical endocrinology 1995;43(1):29-35.
1995: A Weber; Peter J Trainer; Ashley B Grossman; Farhad Afshar; S Medbak; LA Perry; P N Plowman; L H Rees; G Michael Besser; Martin O Savage
Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome.
Clinical endocrinology 1995;43(1):19-28.
1995: Peter J Trainer; M Faria; John Newell-Price; P Browne; P Kopelman; D H Coy; G Michael Besser; Ashley B Grossman
A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis.
The Journal of clinical endocrinology and metabolism 1995;80(2):412-7.
1995: Paul J Jenkins; Peter J Trainer; P N Plowman; W S Shand; Ashley B Grossman; J A H Wass; G Michael Besser
The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome.
The Journal of clinical endocrinology and metabolism 1995;80(1):165-71.
1994: Peter J Trainer; Jeff M P Holly; S Medbak; L H Rees; G Michael Besser
The effect of recombinant IGF-I on anterior pituitary function in healthy volunteers.
Clinical endocrinology 1994;41(6):801-7.
1994: J M Kirk; Peter J Trainer; W H Majrowski; J Murphy; Martin O Savage; G Michael Besser
Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.
Clinical endocrinology 1994;41(4):487-93.
1994: Peter J Trainer; M Besser
Cushing's syndrome. Therapy directed at the adrenal glands.
Endocrinology and metabolism clinics of North America 1994;23(3):571-84.
1994: S L Jones; Peter J Trainer; L Perry; J A H Wass; G M Bessser; Ashley Grossman
An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year.
Clinical endocrinology 1994;41(1):123-8.
1994: Giuseppe Delitala; Peter J Trainer; O Oliva; Giuseppe Fanciulli; Ashley B Grossman
Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man.
The Journal of endocrinology 1994;141(1):163-8.
1994: Peter J Trainer
Effect of insulin-like growth factor I on anterior pituitary function.
Acta paediatrica (Oslo, Norway : 1992). Supplement 1994;399():173-5.
1994: Shern L Chew; J E Dacie; Rodney H Reznek; E C Newbould; R Sheaves; Peter J Trainer; David G Lowe; W S Shand; J Hungerford; G Michael Besser
Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay.
The Quarterly journal of medicine 1994;87(1):49-54.
1993: Peter J Trainer; C Eastment; Ashley B Grossman; M J Wheeler; L Perry; G Michael Besser
The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome.
Clinical endocrinology 1993;39(4):441-3.
1993: J M Vincent; Peter J Trainer; Rodney H Reznek; A J Marcus; J E Dacie; P Armstrong; G Michael Besser
The radiological investigation of occult ectopic ACTH-dependent Cushing's syndrome.
Clinical radiology 1993;48(1):11-7.
1993: J D Walker; Ashley Grossman; J V Anderson; E Ur; Peter J Trainer; J Benn; C Lowy; Peter H Sönksen; P N Plowman; David G Lowe
Malignant prolactinoma with extracranial metastases: a report of three cases.
Clinical endocrinology 1993;38(4):411-9.
1993: A Costa; Peter J Trainer; M Besser; A Grossman
Nitric oxide modulates the release of corticotropin-releasing hormone from the rat hypothalamus in vitro.
Brain research 1993;605(2):187-92.
1993: Peter J Trainer; Jeff M P Holly; S Medbak; G Michael Besser
Effect of recombinant insulin-like growth factor I on anterior pituitary function in healthy volunteers.
Acta paediatrica (Oslo, Norway : 1992). Supplement 1993;388():38; discussion 39.
1993: Peter J Trainer; H S Lawrie; J Verhelst; T A Howlett; David G Lowe; Ashley B Grossman; Martin O Savage; Farhad Afshar; G Michael Besser
Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment.
Clinical endocrinology 1993;38(1):73-8.
1992: Peter J Trainer; J M Kirk; Martin O Savage; Ashley B Grossman; G Michael Besser
Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
The Journal of endocrinology 1992;134(3):513-7.
1991: J A Verhelst; Peter J Trainer; T A Howlett; L Perry; L H Rees; Ashley B Grossman; J A H Wass; G Michael Besser
Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
Clinical endocrinology 1991;35(2):169-78.
1991: J M Kirk; R J M Ross; Peter J Trainer; A L Froud; S C Davies; Martin O Savage; G Michael Besser
Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
Clinical endocrinology 1991;34(5):407-11.
1991: Peter J Trainer; Ashley Grossman
The diagnosis and differential diagnosis of Cushing's syndrome.
Clinical endocrinology 1991;34(4):317-30.
1991: Peter J Trainer; J M Kirk; L McLoughlin; R J Touzel; L Perry; L H Rees; G Michael Besser
The effects on anterior pituitary hormone secretion of salmon calcitonin in healthy volunteers.
Clinical endocrinology 1991;34(4):299-304.
1990: R J M Ross; J M Kirk; S Tsagarakis; Peter J Trainer; E Ciccarelli; R Touzel; Ashley Grossman; Martin O Savage; G Michael Besser
Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion.
Clinical endocrinology 1990;33(2):239-48.
1990: Peter J Trainer; Ashley Grossman
Therapeutic effects of neuroactive drugs on hypothalamo-pituitary in man.
Advances in experimental medicine and biology 1990;274():165-76.